Formulation and evaluation of novel micellar nanocarrier for nasal delivery of sumatriptan

Nanomedicine

Volumn 5, Issue 4, 2010, Pages 575-587

  Jain, Ratnesh ^a   Nabar, Swapna ^b   Dandekar, Prajakta ^a   Hassan, Puthusserickal ^b   Aswal, Vinod ^b   Talmon, Yeshayahu ^c   Shet, Tanuja ^d   Borde, Lalit ^e   Ray, Krishanu ^e   Patravale, Vandana ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b BHABHA ATOMIC RESEARCH CENTRE   (India)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d TATA MEMORIAL HOSPITAL   (India)

^e TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

Author keywords

Autoradiography; Biodistribution; Brain targeting; Micellar nanocarrier; Sumatriptan

Indexed keywords

NANOCARRIER; SUMATRIPTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG UPTAKE; IN VIVO STUDY; MALE; MICELLE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; AUTORADIOGRAPHY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYOELECTRON MICROSCOPY; DRUG CARRIERS; MALE; MICELLES; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; RATS; RATS, WISTAR; SCATTERING, RADIATION; SEROTONIN AGONISTS; SPECTROPHOTOMETRY, ULTRAVIOLET; SUMATRIPTAN; TISSUE DISTRIBUTION;

EID: 77953464626     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.28     Document Type: Article

References (40)

1. Heywood J, Zagami AS: Treating acute migraine attack: guidelines for general practitioners and emergency department doctors. Curr. Ther. 37, 33-37 (1997).
2. Goadsby PJ, Olesen J: Diagnosis and management of migraine. Br. Med. J. 312, 1279-1283 (1996).
3. Goadsby PJ: Diagnosis and optimum treatment of migraine. CNS Drugs 1, 245-253 (1994).
4. Perry CM, Markham A: Sumatriptan: an updated review of its use in migraine. Drugs 55, 889-922 (1998).
5. MacGregor EA: Zolmitriptan clinical studies. Drugs Today 34, 1027-1033 (1998).
6. Chen J, Jiang X, Jiang W, Mei N, Gao X, Zhang Q: High-performance liquid chromatographic analysis of zolmitriptan in human plasma using fluorescence detection. J. Pharm. Biomed. Anal. 35, 639-645 (2004).
7. Vyas TK, Babbar AK, Sharma RK, Misra A: Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J. Drug Target. 13, 317-324 (2005).
8. Bateman DN: Sumatriptan. Lancet 341, 221-224 (1993).
9. Humphrey PP: 5-Hydroxytryptamine and the pathophysiology of migraine. J. Neurol. 238, S38-S44 (1991).
10. Humphrey PP, Feniuk W, Perren MJ et al.: The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 9, 23-33 (1989).
11. Hansen PT, Vries PD, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60, 1259-1287 (2000).
12. Vyas TK, Babbar AK, Sharma RK, Singh S, Misra AN: Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS Pharm. Sci. Tech. 7, E1-E9 (2006).
13. Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RSR: Thermoreversible- mucoadhesive gel for nasal delivery of sumatriptan. AAPS Pharm. Sci. Tech. 7, E1-E7 (2006).
14. Chien YB: Nasal drug delivery and delivery systems. In: Nasal Systemic Drug Delivery. Chien YW, Su KSE, Chang SF (Eds). Marcel Dekker, New York, NY, USA, 239-245 (1989).
15. Illum L: Transport of drugs from the nasal cavity to central nervous system. Eur. J. Pharm. Sci. 11, 1-18 (2000).
16. Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M: Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 49, 1225-1230 (1997).
17. Letchford K, Burt H: A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm. 65, 259-269 (2007).
18. Kwon GS, Kataoka K: Block copolymer micelles as long-circulating drug vehicles. Adv. Drug Deliv. Rev. 16, 295-309 (1995).
19. Torchilin VP: Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24, 1-16 (2007).
20. Jain NJ, Aswal VK, Goyal PS, Bahadur P: Salt induced micellization and micelle structures of PEO/PPO/PEO block copolymers in aqueous solution. Colloids Surf. A 173, 85-94 (2000).
21. Francis MF, Cristea M, Winnik FM: Polymeric micelles for oral drug delivery: why and how. Pure Appl. Chem. 76, 1321-1335 (2004).
22. Gao Y, Li LB, Zhai G: Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin. Colloids Surf. B. 64, 194-199 (2008).
23. United States Pharmacopoeial Convention: United States Pharmacopeia. Asian Edition, USP 27. Rockville, MD, USA (2003).
24. Schillen K, Brown W, Johnson RM: Micellar sphere-to-rod transition in an aqueous triblock copolymer system. A dynamic light scattering study of translational and rotational diffusion. Macromolecules 27, 4825-4832 (1994).
25. Nabar SJ, Jain R, Nayak U, Patravale V: Development of radiolabeling method for sumatriptan nanocarrier as brain targeted intranasal drug delivery system. Ind. J. Nucl. Med. 22, 112-113 (2007).
26. Thorne RG, Emory CR, Ala TA, Frey WH: Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 692, 278-282 (1995).
27. Thomas GH, Hartman JA, Seiden LS: Rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 13, 453-456 (1980).
28. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates (6th Edition). Academic Press, San Diego, CA, USA (1998).
29. Oh KT, Bronich TK, Kabanov AV: Micellar formulations for drug delivery based on mixtures of hydrophobic and hydrophilic Pluronic® block copolymers. J. Control. Release 94, 411-422 (2004).
30. Ivanova R, Lindman B, Alexandridis P: Effect of pharmaceutically acceptable glycols on the stability of the liquid crystalline gels formed by Poloxamer 407 in water. J. Colloid Interface Sci. 252, 226-235 (2002).
31. Xie Y, Wei L, Cao S, Jiang X, Yin M, Tang W: Preparation of bupleurum nasal spray and evaluation on its safety and efficacy. Chem. Pharm. Bull. 54, 48-53 (2006).
32. Hammad MA, Müller BW: Solubility and stability of clonazepam in mixed micelles. Int. J. Pharm. 169, 55-64 (1998).
33. Dai WG, Dong LC, Li S, Deng Z: Combination of Pluronic/vitamin E TPGS as a potential inhibitor of drug precipitation. Int. J. Pharm. 355, 31-37 (2008).
34. Brüsewitz C, Schendler A, Funke A, Wagner T, Lipp R: Novel poloxamer-based nanoemulsions to enhance the intestinal absorption of active compounds. Int. J. Pharm. 329, 173-181 (2007).
35. Bryant G, Thomas JC: Improved particle size distribution measurements using multiangle dynamic light scattering. Langmuir 11, 2480-2485 (1995).
36. Meaney CM, O'Driscoll CM: A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt:fatty acid micellar systems using the CaCo-2 cell culture model. Int. J. Pharm. 207, 21-30 (2000).
37. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496 (2004).
38. Kanayama Y, Enomoto S, Irie T, Amano R: Axonal transport of rubidium and thallium in the olfactory nerve of mice. Nucl. Med. Biol. 32, 505-512 (2005).
39. Haberly LB, Price JL: Association and commissural fiber systems of the olfactory cortex of the rat: I. Systems originating in the piriform cortex and adjacent areas. J. Comp. Neurol. 178, 711-740 (1978).
40. Fechter LD, Johnson DL, Lynch RA: The relationship of particle size to olfactory nerve uptake of a non-soluble form of manganese into brain. Neurotoxicology 23, 177-183 (2002).